In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 44 citations in OpenAlex.

1. Endocarditis Caused by Highly Penicillin-Resistant Viridans Group Streptococci: Still Room for Vancomycin-Based Regimens.Antimicrobial agents and chemotherapy · 2019
   Article
2. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.Therapeutic advances in infectious disease · 2017
   Review
3. Oritavancin diphosphate.Hospital pharmacy · 2014
   Article
4. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.Antimicrobial agents and chemotherapy · 2008
   Article
5. New drugs to treat skin and soft tissue infections.Current infectious disease reports · 2007
   Article
6. Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Antimicrobial agents and chemotherapy · 2004
   Article
7. Glycopeptide antibiotics: from conventional molecules to new derivatives.Drugs · 2004
   Review
8. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.Antimicrobial agents and chemotherapy · 2003
   Article
9. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.Antimicrobial agents and chemotherapy · 2002
   Article
10. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.Antimicrobial agents and chemotherapy · 2001
    Article
11. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.Antimicrobial agents and chemotherapy · 2001
    Article
12. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.Antimicrobial agents and chemotherapy · 2000
    Article
13. Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.Current infectious disease reports · 1999
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as